CTOR Form 4: CEO Mazur Receives 1.7M RSAs and 4.5M Options
Rhea-AI Filing Summary
Leonard L. Mazur, Chief Executive Officer and Director of Citius Oncology, Inc. (CTOR), received equity awards on 09/19/2025 that materially change his beneficial ownership. The Form 4 reports a grant of 1,700,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. The filing also shows outstanding stock options: 800,000 options with a $1.07 exercise price and 3,700,000 options with a $2.15 exercise price, each with multi-year vesting schedules. These awards reflect compensation through equity with time-based vesting conditions tied to continued service.
Positive
- Alignment of interests: Time-based vesting on restricted shares and options ties CEO compensation to continued service and long-term company performance.
- Transparency: Filing discloses specific grant sizes, exercise prices ($1.07 and $2.15) and vesting schedules, enabling investor assessment.
Negative
- Potential dilution: The awards represent 6,200,000 shares when combining restricted stock and underlying options, which could be dilutive if fully vested and exercised.
- Large concentrated grant: A single reporting person received a substantial allocation that may materially affect share overhang depending on company size and outstanding shares.
Insights
TL;DR: Significant CEO equity awards increase management alignment but raise questions about dilution and governance oversight.
The reported restricted stock award of 1,700,000 shares and existing options totaling 4,500,000 underlying shares represent a sizable equity allocation to the CEO. Time-based vesting aligns the CEO with long-term company performance by tying realization to continued service. From a governance perspective, the size and terms of awards warrant disclosure on how compensation was approved and whether independent directors evaluated dilution impact and shareholder interests.
TL;DR: Large equity grants to the CEO materially affect potential share overhang and could impact future per-share metrics.
The Form 4 documents a total of 6,200,000 shares attributable to the reporting person when combining restricted shares and options underlying common stock. Vesting schedules spread potential dilution over three years, which staggers the impact but still creates a meaningful pool of shares that could convert to outstanding common stock if vested and exercised. Investors should note the exercise prices of $1.07 and $2.15 for the options when modeling potential proceeds and dilution scenarios.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,700,000 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
